Clinical significance of end of induction measurable residual disease monitoring in B-cell acute lymphoblastic leukemia: A single center experience.
ALL
MRD
cytogenetics
end of induction
flow cytometry
Journal
Cytometry. Part B, Clinical cytometry
ISSN: 1552-4957
Titre abrégé: Cytometry B Clin Cytom
Pays: United States
ID NLM: 101235690
Informations de publication
Date de publication:
09 Aug 2023
09 Aug 2023
Historique:
revised:
28
06
2023
received:
23
02
2023
accepted:
26
07
2023
medline:
9
8
2023
pubmed:
9
8
2023
entrez:
9
8
2023
Statut:
aheadofprint
Résumé
The assessment of measurable residual disease (MRD) has emerged as a powerful prognostic tool for both pediatric and adult acute lymphoblastic leukemia (ALL). This retrospective study aimed to evaluate the prognostic relevance of the end of induction MRD in B-cell acute lymphoblastic leukemia (B ALL) patients. The study included 481 patients who underwent treatment for B ALL between August 2012 and March 2019 and had their MRD at the end of induction assessed by flow cytometry. Baseline demographic characteristics were collected from the patient's clinical records. Event free survival (EFS) and relapse free survival (RFS) were calculated using Kaplan-Meier analysis and survival estimates were compared using the log-rank test. End of induction MRD and baseline karyotype were the strongest predictors of EFS and RFS on multivariate analysis. The EFS was inversely related to the MRD value and the outcomes were similar in patients without morphological remission at the end of induction and patients in remission with MRD ≥1.0%. Even within the subgroups of ALL based on age, karyotype, BCR::ABL1 translocation and the treatment protocol, end of induction MRD positive patients had poor outcomes compared to patients who were MRD negative. The study outcome would help draft end of induction MRD-based treatment guidelines for the management of B ALL patients.
Identifiants
pubmed: 37555390
doi: 10.1002/cyto.b.22139
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : The Wellcome Trust DBT India Alliance
ID : IA/S/11/2500267
Organisme : The Wellcome Trust DBT India Alliance
ID : IA/CPHS/18/1/503930
Organisme : The Wellcome Trust DBT India Alliance
ID : IA/CPHE/17/1/503351
Informations de copyright
© 2023 International Clinical Cytometry Society.
Références
Arun, A. K., Senthamizhselvi, A., Mani, S., Vinodhini, K., Janet, N. B., Lakshmi, K. M., Abraham, A., George, B., Srivastava, A., Srivastava, V. M., Mathews, V., & Balasubramanian, P. (2017). Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients. International Journal of Laboratory Hematology, 39(3), 235-242.
Arunachalam, A. K., Janet, N. B., Korula, A., Lakshmi, K. M., Kulkarni, U. P., Aboobacker, F. N., Abraham, A., George, B., Balasubramanian, P., & Mathews, V. (2020). Prognostic value of MRD monitoring based on BCR-ABL1 copy numbers in Philadelphia chromosome positive acute lymphoblastic leukemia. Leukemia & Lymphoma, 61(14), 3468-3475.
Bajel, A., George, B., Mathews, V., Viswabandya, A., Kavitha, M. L., Srivastava, A., & Chandy, M. (2007). Adult ALL: Treatment outcome and prognostic factors in an Indian population using a modified German ALL (GMALL) protocol. Leukemia, 21(10), 2230-2233.
Bar, M., Wood, B. L., Radich, J. P., Doney, K. C., Appelbaum, F. R., & Gooley, T. A. (2012). Impact of minimal residual disease, as detected by multiparametric flow cytometry pre and post transplantation, on outcome of myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia. Blood, 120(21), 592.
Bar, M., Wood, B. L., Radich, J. P., Doney, K. C., Woolfrey, A. E., Delaney, C., Appelbaum, F. R., & Gooley, T. A. (2014). Impact of minimal residual disease, detected by flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia. Leukemia Research and Treatment, 2014, 421723.
Bassan, R., Brüggemann, M., Radcliffe, H. S., Hartfield, E., Kreuzbauer, G., & Wetten, S. (2019). A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia. Haematologica, 104(10), 2028-2039.
Bassan, R., Intermesoli, T., Scattolin, A., Viero, P., Maino, E., Sancetta, R., Carobolante, F., Gianni, F., Stefanoni, P., Tosi, M., Spinelli, O., & Rambaldi, A. (2017). Minimal residual disease assessment and risk-based therapy in acute lymphoblastic leukemia. Clinical Lymphoma, Myeloma & Leukemia, 17S, S2-S9.
Bassan, R., Spinelli, O., Oldani, E., Intermesoli, T., Tosi, M., Peruta, B., Rossi, G., Borlenghi, E., Pogliani, E. M., Terruzzi, E., Fabris, P., Cassibba, V., Lambertenghi-Deliliers, G., Cortelezzi, A., Bosi, A., Gianfaldoni, G., Ciceri, F., Bernardi, M., Gallamini, A., … Rambaldi, A. (2009). Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood, 113(18), 4153-4162.
Borowitz, M. J., Wood, B. L., Devidas, M., Loh, M. L., Raetz, E. A., Salzer, W. L., Nachman, J. B., Carroll, A. J., Heerema, N. A., Gastier-Foster, J. M., Willman, C. L., Dai, Y., Winick, N. J., Hunger, S. P., Carroll, W. L., & Larsen, E. (2015). Prognostic significance of minimal residual disease in high risk B-ALL: A report from Children's oncology group study AALL0232. Blood, 126(8), 964-971.
Brown, P. A., Shah, B., Advani, A., Aoun, P., Boyer, M. W., Burke, P. W., DeAngelo, D. J., Dinner, S., Fathi, A. T., Gauthier, J., Jain, N., Kirby, S., Liedtke, M., Litzow, M., Logan, A., Luger, S., Maness, L. J., Massaro, S., Mattison, R. J., … Campbell, M. (2021). Acute lymphoblastic leukemia, version 2.2021, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network, 19(9), 1079-1109.
Brüggemann, M., & Kotrova, M. (2017). Minimal residual disease in adult ALL: Technical aspects and implications for correct clinical interpretation. Hematology, ASH Education Program, 2017(1), 13-21.
Cazzaniga, G., De Lorenzo, P., Alten, J., Röttgers, S., Hancock, J., Saha, V., Castor, A., Madsen, H. O., Gandemer, V., Cavé, H., Leoni, V., Köhler, R., Ferrari, G. M., Bleckmann, K., Pieters, R., van der Velden, V., Stary, J., Zuna, J., Escherich, G., … Biondi, A. (2018). Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies. Haematologica, 103(1), 107-115.
Ceppi, F., Duval, M., Leclerc, J. M., Laverdiere, C., Delva, Y. L., Cellot, S., Teira, P., & Bittencourt, H. (2016). Improvement of the outcome of relapsed or refractory acute lymphoblastic leukemia in children using a risk-based treatment strategy. PLoS One, 11(9), e0160310.
Cherian, S., Miller, V., McCullouch, V., Dougherty, K., Fromm, J. R., & Wood, B. L. (2018). A novel flow cytometric assay for detection of residual disease in patients with B-lymphoblastic leukemia/lymphoma post anti-CD19 therapy. Cytometry Part B, Clinical Cytometry, 94(1), 112-120.
Conter, V., Bartram, C. R., Valsecchi, M. G., Schrauder, A., Panzer-Grümayer, R., Möricke, A., Aricò, M., Zimmermann, M., Mann, G., De Rossi, G., Stanulla, M., Locatelli, F., Basso, G., Niggli, F., Barisone, E., Henze, G., Ludwig, W. D., Haas, O. A., Cazzaniga, G., … Schrappe, M. (2010). Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: Results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood, 115(16), 3206-3214.
Dhédin, N., Huynh, A., Maury, S., Tabrizi, R., Beldjord, K., Asnafi, V., Thomas, X., Chevallier, P., Nguyen, S., Coiteux, V., Bourhis, J. H., Hichri, Y., Escoffre-Barbe, M., Reman, O., Graux, C., Chalandon, Y., Blaise, D., Schanz, U., Lhéritier, V., … GRAALL group. (2015). Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia. Blood, 125(16), 2486-2496.
Dongen, J. J. M., Van der Velden, V. H. J., Brüggemann, M., & Orfao, A. (2015). Minimal residual disease diagnostics in acute lymphoblastic leukemia: Need for sensitive, fast, and standardized technologies. Blood, 125(26), 3996-4009.
Gökbuget, N., Kneba, M., Raff, T., Trautmann, H., Bartram, C. R., Arnold, R., Fietkau, R., Freund, M., Ganser, A., Ludwig, W. D., Maschmeyer, G., Rieder, H., Schwartz, S., Serve, H., Thiel, E., Brüggemann, M., Hoelzer, D., & German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia. (2012). Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood, 120(9), 1868-1876.
Hoelzer, D. (2015). Personalized medicine in adult acute lymphoblastic leukemia. Haematologica, 100(7), 855-858.
Hoelzer, D., Bassan, R., Dombret, H., Fielding, A., Ribera, J. M., Buske, C., & ESMO Guidelines Committee. (2016). Acute lymphoblastic leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 27(Suppl 5), v69-v82.
Jain, P., Korula, A., Deshpande, P., Pn, N., Abu Alex, A., Abraham, A., Srivastava, A., Janet, N. B., Lakshmi, K. M., Balasubramanian, P., George, B., & Mathews, V. (2018). Adult acute lymphoblastic leukemia: Limitations of intensification of therapy in a developing country. JCO Global Oncology, 4, 1-12.
Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Martinelli, G., Liedtke, M., Stock, W., et al. (2016). Inotuzumab ozogamicin versus standard care for acute lymphoblastic leukemia. The New England Journal of Medicine, 375(8), 740-753.
Kantarjian, H. M., O'Brien, S., Smith, T. L., Cortes, J., Giles, F. J., Beran, M., Pierce, S., Huh, Y., Andreeff, M., Koller, C., Ha, C. S., Keating, M. J., Murphy, S., & Freireich, E. J. (2000). Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 18(3), 547-561.
Lee, S., Kim, D. W., Cho, B. S., Yoon, J. H., Shin, S. H., Yahng, S. A., Lee, S. E., Eom, K. S., Kim, Y. J., Chung, N. G., Kim, H. J., Min, C. K., Lee, J. W., Min, W. S., & Park, C. W. (2012). Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia, 26(11), 2367-2374.
National Cancer Institute [Internet]. (2011). NCI Dictionary of Cancer Terms. https://www.cancer.gov/publications/dictionaries/cancer-terms
Patkar, N., Alex, A. A., Ahmed, R., Abraham, A., George, B., Vishwabandya, A., Srivastava, A., & Mathews, V. (2012). Standardizing minimal residual disease by flow cytometry for precursor B lineage acute lymphoblastic leukemia in a developing country. Cytometry Part B, Clinical Cytometry, 82B(4), 252-258.
Pieters, R., de Groot-Kruseman, H., Van der Velden, V., Fiocco, M., van den Berg, H., de Bont, E., et al. (2016). Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: Study ALL10 from the Dutch childhood oncology group. Journal of Clinical Oncology, 34(22), 2591-2601.
Pui, C. H., Pei, D., Coustan-Smith, E., Jeha, S., Cheng, C., Bowman, W. P., Sandlund, J. T., Ribeiro, R. C., Rubnitz, J. E., Inaba, H., Bhojwani, D., Gruber, T. A., Leung, W. H., Downing, J. R., Evans, W. E., Relling, M. V., & Campana, D. (2015). Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: A prospective study. The Lancet Oncology, 16(4), 465-474.
Samra, B., Jabbour, E., Ravandi, F., Kantarjian, H., & Short, N. J. (2020). Evolving therapy of adult acute lymphoblastic leukemia: State-of-the-art treatment and future directions. Journal of Hematology & Oncology, 13(1), 70.
Spinelli, O., Peruta, B., Tosi, M., Guerini, V., Salvi, A., Zanotti, M. C., Oldani, E., Grassi, A., Intermesoli, T., Mico, C., Rossi, G., Fabris, P., Lambertenghi-Deliliers, G., Angelucci, E., Barbui, T., Bassan, R., & Rambaldi, A. (2007). Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. Haematologica, 92(5), 612-618.
Tembhare, P. R., Subramanian, P. G., Ghogale, S., Chatterjee, G., Patkar, N. V., Gupta, A., Shukla, R., Badrinath, Y., Deshpande, N., Narula, G., Rodrigues, P., Girase, K., Dhaliwal, D., Prasad, M., Shetty, D., Banavali, S., & Gujral, S. (2020). A high-sensitivity 10-color flow cytometric minimal residual disease assay in B-lymphoblastic leukemia/lymphoma can easily achieve the sensitivity of 2-in-106 and is superior to standard minimal residual disease assay: A study of 622 patients. Cytometry. Part B, Clinical Cytometry, 98(1), 57-67.
Theunissen, P., Mejstrikova, E., Sedek, L., van der Sluijs-Gelling, A. J., Gaipa, G., Bartels, M., Sobral da Costa, E., Kotrová, M., Novakova, M., Sonneveld, E., Buracchi, C., Bonaccorso, P., Oliveira, E., Te Marvelde, J. G., Szczepanski, T., Lhermitte, L., Hrusak, O., Lecrevisse, Q., Grigore, G. E., … EuroFlow Consortium. (2017). Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. Blood, 129(3), 347-357.
Vora, A., Goulden, N., Mitchell, C., Hancock, J., Hough, R., Rowntree, C., Moorman, A. V., & Wade, R. (2014). Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): A randomised controlled trial. The Lancet Oncology, 15(8), 809-818.
Vora, A., Goulden, N., Wade, R., Mitchell, C., Hancock, J., Hough, R., Rowntree, C., & Richards, S. (2013). Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): A randomised controlled trial. The Lancet Oncology, 14(3), 199-209.
Yeoh, A. E. J., Ariffin, H., Chai, E. L. L., Kwok, C. S. N., Chan, Y. H., Ponnudurai, K., Campana, D., Tan, P. L., Chan, M. Y., Kham, S. K. Y., Chong, L. A., Tan, A. M., Lin, H. P., & Quah, T. C. (2012). Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: Results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study. Journal of Clinical Oncology, 30(19), 2384-2392.